Development of a new vaccine for the prevention of Lassa fever.
about
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesEffective post-exposure treatment of Ebola infectionCurrent ebola vaccinesMucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responsesArenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategiesAdvanced vaccine candidates for Lassa feverEnvelope exchange for the generation of live-attenuated arenavirus vaccinesA recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.Rodent-borne diseases and their risks for public healthGlobal research trends of World Health Organization's top eight emerging pathogens.Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.T cell-dependence of Lassa fever pathogenesis.VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections.Comparative pathogenesis and systems biology for biodefense virus vaccine development.Forty years of the war against Ebola.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.Vesicular stomatitis virus-based vaccines against Lassa and Ebola virusesCross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.Reverse genetics approaches to combat pathogenic arenavirusesSingle-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.Pathogenesis of arenavirus hemorrhagic fevers.The curious case of arenavirus entry, and its inhibition.Multifunctional nature of the arenavirus RING finger protein Z.Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trialsPathogenesis of Lassa fever in cynomolgus macaques.Identification of protective Lassa virus epitopes that are restricted by HLA-A2.Nonsegmented negative-strand viruses as vaccine vectors.Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to manProtective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infectionA recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.Development of live-attenuated arenavirus vaccines based on codon deoptimizationFunctional interferon system is required for clearance of lassa virus.Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.Progress in filovirus vaccine development: evaluating the potential for clinical use.
P2860
Q21131585-A692BE08-C85F-4F87-870A-749537B4B900Q21131616-6E980A2C-3E4E-454B-9FCA-F31BD9D84FABQ21534720-FE9C6389-811C-4B84-AD26-C100F6A1C9F7Q21562420-B8177EE6-1554-4671-A97B-907579BFF647Q24599295-AC04D731-63BF-4A96-9A6C-773D1BCD7C22Q26823627-2980B1E0-231B-4E02-89EB-59DA1F8C0F84Q27320211-AF35BBD2-20E8-47E8-89B7-44E600F571A3Q27473027-365A4A83-400F-4294-A7BC-463701C65F8EQ28249580-89D440E5-663C-4BCD-81B0-E397E766489FQ30151375-E13C3294-EA09-4A77-988F-B88396759FBDQ33383772-D90FC2A8-E1B6-4013-9C8F-AE07D37F4393Q33548699-91B3AC7B-493E-40D7-8681-7FCE4741FCADQ33723534-75979242-6667-4657-AA93-4C381241BC9DQ33725635-4A0654ED-8055-45BF-81D1-C1F682B5BA2EQ33887328-982BFEBB-8B6F-423D-9FEE-1E9480BE5BADQ33959989-7475140E-3144-480C-84FA-C84FA48E1D6CQ34173952-08DE5CE0-18B0-4257-A37B-DC41EB46CACBQ34322342-80C5B846-B84F-4048-85C0-E3FABCF034E4Q34459935-929E5840-21BC-4489-B6A1-018DF3D2243CQ34566171-63BDA867-7026-440F-BF2A-4A5F3A8EEB51Q34596958-0458D651-D295-4C9D-8025-776E8CE19AC9Q34606818-5A14A4E3-D855-42F4-A487-1E4B8BEC6F08Q34625899-554D6C73-BF9E-44C4-BB9A-2CE9039BE81DQ34636037-3111FC9D-5015-47D6-A432-647BB902F131Q34645925-D37291FF-5E06-45CA-882F-76E7CF75B930Q34647625-3A551359-19AD-46EA-905E-A98F2B32C42EQ34671806-EDC9C539-C5C6-40E8-8982-9D7CC6759E26Q35014564-3D10283C-219F-4EA5-A613-B8DF6A1670DBQ35024149-AC395EB0-8FFF-49D8-86A2-2C0BDF828920Q35139219-F0BBE6F3-6586-48BE-9C26-D804167FAF83Q35248863-ADB5DB0F-A162-4D14-B031-CBACF8F01BFCQ35300104-2E82340E-92D3-4847-BB20-F2B69FD72602Q35463993-FE40C362-B309-44C2-B30E-5565C54EA08AQ35487706-EEE46BEF-C661-486D-A315-A21AC031F394Q35826301-D55AC414-3ACA-4100-B0E1-7C8DA89157C6Q35826698-8892D70B-D9E9-45CE-A1BC-FADF1F97AAE4Q35847032-B806FCBE-A12B-4F2F-BF18-5073FE765F9FQ35870592-BEA251A7-2B5B-4415-9B02-68A6A42FCAE5Q36099144-40D7C82C-6DEC-46AE-855B-BA82A7F37CB3Q36100545-0D0B99EA-D235-45F6-9F28-00DDA85941EC
P2860
Development of a new vaccine for the prevention of Lassa fever.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Development of a new vaccine for the prevention of Lassa fever
@nl
Development of a new vaccine for the prevention of Lassa fever.
@ast
Development of a new vaccine for the prevention of Lassa fever.
@en
Development of a new vaccine for the prevention of Lassa fever.
@en-gb
type
label
Development of a new vaccine for the prevention of Lassa fever
@nl
Development of a new vaccine for the prevention of Lassa fever.
@ast
Development of a new vaccine for the prevention of Lassa fever.
@en
Development of a new vaccine for the prevention of Lassa fever.
@en-gb
altLabel
Development of a New Vaccine for the Prevention of Lassa Fever
@en
prefLabel
Development of a new vaccine for the prevention of Lassa fever
@nl
Development of a new vaccine for the prevention of Lassa fever.
@ast
Development of a new vaccine for the prevention of Lassa fever.
@en
Development of a new vaccine for the prevention of Lassa fever.
@en-gb
P2093
P2860
P50
P921
P1433
P1476
Development of a new vaccine for the prevention of Lassa fever.
@en
P2093
Amy C Shurtleff
Bianca R Mothé
Elizabeth A Fritz
Joan B Geisbert
Kathleen M Daddario
Lisa Fernando
Mary C Guttieri
Ryan Liebscher
Steven Jones
Tom Larsen
P2860
P356
10.1371/JOURNAL.PMED.0020183
P407
P577
2005-06-28T00:00:00Z